Robert I. Blum, President and CEO of Cytokinetics Inc (NASDAQ:CYTK), filed a Form 4 on September 15, 2026, disclosing a series of transactions in common stock dated September 14-15, 2026, including option exercises, open-market sales, charitable gifts, and trust transfers.
Key Highlights
- Option exercise: Blum exercised 7,500 non-qualified stock options at $10.60 per share on September 14, 2026, pursuant to a Rule 10b5-1 trading plan.
- Direct shares sold: 7,500 shares of common stock were sold at $73.44 per share on September 14, 2026, under the same 10b5-1 plan.
- Charitable gift: 1,350 shares were gifted at $0 on September 14, 2026.
- Trust transfer: 97,926 shares were transferred to The Bridget Blum 2026 Irrevocable Trust on September 14, 2026, with beneficial ownership disclaimed by the reporting person.
- Trust sale: The Bridget Blum 2026 Irrevocable Trust sold 97,926 shares at $69.33 per share on September 15, 2026; Blum disclaims beneficial ownership of the shares sold or proceeds.
- Remaining direct ownership: Following all transactions, Blum directly held 278,544 shares of common stock, plus 156,745 non-qualified stock options.
Blum's September 2026 Transactions in Cytokinetics Common Stock
According to the filing, Robert I. Blum, who serves as both Director and President and CEO of Cytokinetics Inc, executed multiple transactions on September 14, 2026 under a pre-established Rule 10b5-1 trading plan. He exercised 7,500 non-qualified stock options at a conversion price of $10.60 per share, acquiring 7,500 shares of common stock. Those shares were then sold the same day at $73.44 per share. The filing notes that both the exercise and the sale were made pursuant to a trading plan intended to satisfy the conditions of Rule 10b5-1(c).
Separately, the filing discloses that Blum made a charitable gift of 1,350 shares at $0 on September 14, 2026. On the same date, he transferred 97,926 shares to The Bridget Blum 2026 Irrevocable Trust, of which he is a co-trustee. The filing states that Blum "disclaims any beneficial ownership interest in the shares held by the aforementioned trust upon completion of the gift transfer." The trust then sold those 97,926 shares on September 15, 2026 at $69.33 per share, and the filing again states that Blum "disclaims any beneficial ownership interest in the shares sold or the proceeds thereof."
After all reported transactions, Blum's direct beneficial ownership stood at 278,544 shares. The filing also discloses indirect holdings of 2,083 shares each in The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, both of which Blum co-trustees; beneficial ownership is disclaimed in both cases. In addition, 97,926 shares are held indirectly by The Bridget Blum 2026 Irrevocable Trust, though following the September 15, 2026 sale, that trust's balance is reported as 0. Blum retains 156,745 non-qualified stock options directly.
What Was Disclosed
The filing reports an option exercise, two open-market sales, a charitable gift, and trust-related transfers by Cytokinetics' President and CEO on September 14-15, 2026, with all sales and the option exercise conducted under a Rule 10b5-1 trading plan.




Please wait processing your request...